

## Ordering information

### Instrument

- HYDRASYS 2 Scan Focusing .....1202

### Accessories

- HYDRASHIFT 2/4 Accessories (Applicator carrier specific for HYDRASHIFT) .....1251

### Controls/ Calibrators

- isatuximab control .....4764

### Consumables

- Applicators Green HYDRASHIFT (10 individual Applicators green) .....4195

### Reagents

- HYDRASHIFT 2/4 isatuximab (40 tests) .....4642
- HYDRAGEL 2 IF Acid violet Dynamic Mask .....4302
- HYDRAGEL 4 IF Acid violet Dynamic Mask .....4304
- Antisera and Fixative for immunofixation IF Dynamic Mask .....4315
- HYDRAGEL 2 IF Acid violet Standard Mask .....4802
- HYDRAGEL 4 IF Acid violet Standard Mask .....4804
- Antisera and Fixative for immunofixation IF Standard Mask .....4815

# HYDRASHIFT avoids isatuximab interference on IMMUNOFIXATION



**Sebia** | RCS Evry 672 041 902 | Parc technologique Léonard de Vinci | 27, rue Léonard de Vinci | CP 8010 Lisses | 91008 Evry cedex | France | Tel.: +33 1 69 89 80 80 | E-mail: sebia@sebia.com | [www.sebia.com](http://www.sebia.com)

**Benelux** | Tel: +32 2 702 64 64 (BE) | Tel: +31 20 610 8099 (NL) | E-mail: sebia.benelux@sebia.com • **Brasil** | Tel: +55 11 3849 0148 | E-mail: brasil@sebia.com  
**Canada** | Tel: +1 (888) 725-3013 | Fax: +1 (438) 380-3780 | E-mail: canada@sebia.com • **China** | Tel: +86 (21) 6360 1436 | Fax: +86 (21) 6361 2011 | E-mail: china@sebia.com • **Germany & Austria** | Tel: +49 (0) 661 33081 | Fax: +49 (0) 661 31881 | E-mail: sebia@sebia.de • **India** | Tel: +91 124 4262100 | E-mail: sebiaindia@sebia.com • **Italy** | Tel: +39 055 24851 | Fax: +39 055 0982083 | E-mail: info@sebia.it • **Japan** | Tel: (03) 5830-0139 | Fax: (03) 5830-0140  
**Portugal** | Tel: +351 211 224 653 | Fax: +351 211 305 079 | E-mail: portugal@sebia.com • **Spain** | Tel: +34 93 208 15 52 | Fax: +34 93 458 55 86 | E-mail: sebia@sebia.es • **Singapore** | Tel: +65 6223 2273 | E-mail: singapore@sebia.com • **Switzerland** | Tel: +41 44 787 88 10 | E-mail: contact.ch@sebia.com  
**UK** | Tel: +44 (0)1276 600636 | Fax: +44 (0)1276 38827 | E-mail: sales@sebia.co.uk • **UAE** | Tel: +971 (0)4 878 69 77 • **USA** | Tel: +1 (770) 446-3707 - Fax: +1 (770) 446-8511 | E-mail: info@sebia-usa.com

©2021 Sebia - Non-contractual illustration - 07/2021 - Ref: HSIBIEN - Sebia reserves the right to modify at any time and without notice the information contained in this document intended for healthcare professionals. This document contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Carefully read the instructions in the reagent package inserts and instrument manuals.

## What is SARCLISA®

SARCLISA® (isatuximab-irfc) is a human monoclonal antibody (mAb) targeting CD38 used in Multiple Myeloma (MM) treatment regimens.

IF is one of the tests referenced in the IMWG guidelines to assess the complete response to treatment in a patient with MM.



Treatments with mAb can affect the interpretation on immunofixation (IF) tests.



## HYDRASHIFT avoids isatuximab interference on IF

HYDRASHIFT isatuximab is a unique «shift» technology to avoid isatuximab interference using HYDRAGEL 2/4 IF on HYDRASYS 2 platforms.


Easy to implement: no sample pre-treatment, same IF protocol.



## Clinical case example



**Date of Birth:** March 23rd, 1952  
**Pathology:** Multiple Myeloma  
**Serum Peak:** IgG Kappa



\* Contact your Sebia representative for other regulatory approvals